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Dermatological adverse events (AEs) are an existing concern dur-
ing hepatitis C virus (HCV) infection and peginterferon/ribavirin
treatment. HCV infection leads to dermatological and muco-
cutaneous manifestations including small-vessel vasculitis as
part of the mixed cryoglobulinemic syndrome. Peginterferon/
ribavirin treatment is associated with well-characterized derma-
tological AEs tending towards a uniform entity of dermatitis. New
direct-acting antivirals have led to signiﬁcant improvements in
sustained virologic response rates, but several have led to an
increase in dermatological AEs versus peginterferon/ribavirin
alone. In telaprevir trials, approximately half of treated patients
had rash. More than 90% of these events were Grade 1 or 2
(mild/moderate) and in the majority (92%) of cases, progression
to a more severe grade did not occur. In a small number of cases
(6%), rash led to telaprevir discontinuation, whereupon symp-
toms commonly resolved. Dermatological AEs with telaprevir-
based triple therapy were generally similar to those observed
with peginterferon/ribavirin (xerosis, pruritus, and eczema). A
few cases were classiﬁed as severe cutaneous adverse reactionJournal of Hepatology 20
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Abbreviations: AE, adverse event; HCV, hepatitis C virus; SCAR, severe cutane-
ous adverse reaction; MC, mixed cryoglobulinemia; IgM, immunoglobulin M;
RF, rheumatoid factor; PCT, porphyria cutanea tarda; RR, risk ratio; CI, conﬁ-
dence interval; DAA, direct-acting antiviral; T12PR, telaprevir 750 mg every 8 h
for 12 weeks, in combination with peginterferon/ribavirin, followed by pegin-
terferon/ribavirin alone; SSC, special search criteria; SJS, Stevens–Johnson sy-
ndrome; DRESS, drug reaction with eosinophilia and systemic symptoms; TEN,
toxic epidermal necrolysis; DHS, drug-induced hypersensitivity syndrome; EM,
erythema multiforme; AGEP, acute generalized exanthematous pustulosis.(SCAR), also referred to as serious skin reactions, a group of rare
conditions that are potentially life-threatening. It is therefore
important to distinguish between telaprevir-related dermatitis
and SCAR. The telaprevir prescribing information does not
require telaprevir discontinuation for Grade 1 or 2 (mild/moder-
ate) rash, which can be treated using emollients/moisturizers and
topical corticosteroids. For Grade 3 rash, the prescribing informa-
tion mandates immediate telaprevir discontinuation, with ribavi-
rin interruption (with or without peginterferon) within 7 days of
stopping telaprevir if there is no improvement, or sooner if it
worsens. In case of suspicion or conﬁrmed diagnosis of SCAR,
all study medication must be discontinued.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Infection with the hepatitis C virus (HCV) results in various clin-
ical manifestations in addition to inﬂammatory and ﬁbrotic
injury to the liver [1,2]. Common among these are dermatological
conditions and systemic disorders affecting the skin [3]. In some
cases, cutaneous signs or symptoms may provide the ﬁrst and
only clue to the existence of an underlying HCV infection [4].
Treatment of dermatological manifestations of HCV through
eradication of the virus is therefore important in effective patient
management, although this alone is not a major justiﬁcation for
HCV treatment [5]. Existing and in-development antiviral thera-
pies, however, are also associated with dermatological adverse
events (AEs). In addition to reviewing the dermatological mani-
festations of HCV and its treatments, this paper provides practical
guidance on the diagnosis and appropriate management of rash
events during treatment with the recently approved HCV prote-
ase inhibitor telaprevir, in order that their impact on treatment
outcomes can be limited.12 vol. 56 j 455–463
Table 1. Cutaneous diseases strongly linked to HCV infection.
Mixed cryoglobulinemia [3] 40 to 84% of HCV-infected 
individuals produce 
cryoglobulins; 
15% will develop 
cryoglobulinemia vasculitis. 
Vasculitis is mostly cutaneous 
but can be systemic if severe
Porphyria cutanea tarda [3, 6] Most common viral infection 
associated with PCT. Prevalence 
of HCV infection in PCT cases 
varies geographically
Lichen planus [7] Strongly correlated with HCV 
infection in meta-analysis
ReviewCutaneous diseases strongly linked to HCV infection
There are several cutaneous conditions that have a strong associ-
ation with HCV infection. These are outlined below and summa-
rized in Table 1.Mixed cryoglobulinemia
Mixed cryoglobulinemia (MC) is a systemic vasculitis that affects
mainly the small and, less frequently, medium-sized vessels and
is attributable to the expansion of B cells producing pathogenic
immunoglobulin M (IgM) with rheumatoid factor (RF) activity.
MC leads to clinical manifestations ranging from the so-called
MC syndrome (purpura often with skin ulcers, arthralgia, and
asthenia) to lesions with neurological and renal involvement
due to small-vessel vasculitis [8,9]. In a prospective study of
1614 HCV-infected patients, 40% experienced MC, and 15% devel-
oped MC vasculitis [3] Up to 80–90% of MC vasculitis cases are
associated with HCV infection [8,9] In addition to eradication of
HCV infection and symptomatic alleviation, treatment of MC
aims to suppress B-cell clonal expansion and cryoglobulin pro-
duction. The choice of the most appropriate treatment is depen-
dent on the extent of disease activity and organ involvement
[8,10].Table 2. Localized and generalized cutaneous reactions to interferon. (See
below-mentioned references for further information.)
Localized reactions Erythematous or eczematous 
dermatitis and psoriasis [16, 19]
Localized alopecia associated with local 
cutaneous reactions to interferon [20]
Skin ulceration and necrosis [21]
Local infections and local allergic 
reactions to interferon injection [16]
Generalized reactions Alopecia/hair growth anomalies [16]
Skin xerosis, dermatitis and pruritus 
[16, 22]
skin, such as lichen planus or psoriasis, 
Chronic inflammatory diseases of the 
which may be induced or exacerbated 
by interferon [16, 19]
Autoimmune disorders and 
immune-mediated inflammatory disease
(e.g. psoriasis and sarcoidosis) [23, 24]Porphyria cutanea tarda
HCV is the most common viral infection associated with por-
phyria cutanea tarda (PCT), reported in 70–90% of PCT cases in
southern Europe and 20% in northern Europe where infection is
less prevalent and sunlight exposure is lower [6]. Presentation
usually involves vesiculobullous eruption on skin exposed to
ultraviolet light such as the back of the hands and the face,
caused by deposits of uro- and heptacarboxy-porphyrins in the
skin, which promote photon-driven formation of singlet oxygen
species [6,11]. These excess porphyrins are produced chieﬂy in
the liver, and impaired liver function relating to high hepatic iron
levels may provide a clue to a causal link between HCV and PCT
that is yet to be fully established. Ribavirin-associated haemolysis
will increase the iron load in treated patients with chronic hepa-
titis C and may trigger symptomatic PCT.456 Journal of Hepatology 201Lichen planus
Like PCT, the causal relationship between lichen planus and HCV
is unclear [12] Nevertheless, a recent Cochrane meta-analysis
found strong correlation between the two conditions. The risk
of HCV infection was signiﬁcantly higher for patients with lichen
planus than for those without, while individuals infected with
HCV also had an increased risk of having lichen planus [7].
Pruritus and other skin conditions
While pruritus is reported frequently in HCV-infected individu-
als, [3,13–15] it is also a symptom of a range of hepatic co-mor-
bitities that are common in HCV-infected individuals. It is not
possible, therefore, to rule out other liver-related causes for pru-
ritus besides the HCV infection itself [6,16].
Association with HCV infection has been suggested for cutane-
ous polyarteris nodosa [17], and for a variety of other dermato-
logical conditions including psoriasis, urticaria, and erythema
multiforme (EM) [6]. However, most reported associations lacked
sufﬁcient evidence to establish a strong causal link with HCV.Dermatological adverse events on peginterferon/ribavirin-
based HCV treatment
Dermatological AEs with pegylated interferon alfa-2a or alfa-2b
plus ribavirin are well known, accounting for >10% of all inter-
feron-associated side effects [18]. There is some overlap between
the safety proﬁle of interferon-based regimens and other HCV-
associated dermatological conditions, meaning distinguishing
between infection and treatment in terms of causality may be dif-
ﬁcult [16]. Other miscellaneous side effects have been reported,
such as hair growth abnormalities and skin pigmentation, and
are reviewed elsewhere [16].
Interferon monotherapy has dermatological side effects [19],
which can be classiﬁed into localized (limited to the injection
site) and generalized reactions (Table 2) [16]. Addition of ribavi-
rin to the interferon therapy further increases the risk of derma-
titis compared with interferon monotherapy (risk ratio (RR) 1.67,
95% conﬁdence interval (CI) 1.21–2.30), including pruritus (RR2 vol. 56 j 455–463
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1.62, 95% CI 1.29–2.02), and rash (RR 1.74, 95%CI 1.17–2.61), as
demonstrated in a recent Cochrane meta-analysis [25].
Dermatological adverse events with peginterferon/ribavirin
combination therapy tend towards a uniform entity of dermatitis,
characterized by generalized pruritus and skin xerosis, with ecze-
matiform lesions accentuated by erythematous papules and
microvesicles that are often excoriated, predominantly located
on the extremities and on truncal skin sites exposed to friction
[22]. Management of these eruptions can be achieved with the
same approach as for eczema (topical corticosteroids and emol-
lients), usually without the need for discontinuation of the anti-
viral treatment [16].Skin reactions with HCV direct-acting antiviral agents
The recent approval by the US FDA of the new HCV direct-acting
antivirals (DAAs) Boceprevir [26], and Telaprevir [27] as part of
triple combination therapy with the existing peginterferon/riba-
virin regimen has begun a new era in HCV treatment. Phase III tri-
als of DAA-based combination therapy in treatment-naïve and
previously treated HCV genotype 1-infected patients indicate
that signiﬁcant improvements in sustained virological response
rates can be achieved compared with peginterferon/ribavirin
alone [28–31]. Furthermore, DAAs offer the potential to reduce
overall treatment duration to less than 48 weeks in around half
of treatment-naïve patients.
The new treatment era, however, will bring additional
patient management considerations for HCV-treating physicians.In
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Fig. 1. Incidence of rash (SSC) in telaprevir Phase II/III placebo-controlled
trials in patients receiving telaprevir for 12 weeks in combination with
peginterferon/ribavirin, followed by peginterferon/ribavirin alone (T12PR).
(A) Overall incidence during the telaprevir/placebo treatment phase in the T12PR
and PR arms; (B) incidence by Grade during the telaprevir treatment phase in the
T12PR arms only; (C) incidence of rash in the T12PR and PR arms during the
telaprevir/placebo treatment phase by 4-week periods and during the overall
treatment phase by 12-week periods [36,37].
Journal of Hepatology 201Dermatological AEs in particular have been reported with a
higher frequency in trials of the HCV protease inhibitors telapre-
vir, [28,29,32–34] boceprevir [30,31], and BI 201335 [35] as part
of triple combination regimens than with peginterferon/ribavirin
alone. Furthermore, rash and photosensitivity with BI 201335
appeared to be dose-dependent in Phase IIb trials, with higher
rates of moderate and severe rash, and discontinuation due to
rash and photosensitivity, reported in patients receiving a higher
dose [35]. The mechanism of these side effects is currently
unclear, although these preliminary data suggest that the man-
agement of dermatological reactions will remain important going
forwards.
Data from Phase II/III telaprevir clinical trials
Primary efﬁcacy and safety results from ﬁve placebo-controlled
Phase II/III trials of telaprevir (PROVE1, PROVE2, PROVE3,
ADVANCE, and REALIZE), in which 2012 patients received at least
one dose of telaprevir and 764 patients received at least one dose
of placebo, have recently been reported in detail [28,29,32–34].
Within this population, 1346 patients received the standard dose
of telaprevir: 750 mg every 8 h, for 12 weeks, in combination
with peginterferon/ribavirin, followed by peginterferon/ribavirin
alone (T12PR). Herein we describe a pooled analysis of the der-
matological safety proﬁle of telaprevir in these patients.
Dermatological AEs were recorded using special search cate-
gories (SSC) for ‘rash’ and ‘pruritus’. A full characterization of
the skin eruptions, and potential underlying mechanisms, will
be presented elsewhere, but the majority of events recorded with
the ‘rash’ SSC term can be more accurately described as eczema-
tous dermatitis, associated with pruritus, and xerosis. Here, how-
ever, we use the SSC terms ‘rash’ and pruritus consistent with the
reporting of the clinical trial results.
During the telaprevir/placebo treatment phase, rash, and pru-
ritus were among the AEs occurring more frequently (>5% differ-
ence) with telaprevir than placebo. During the telaprevir/placebo
dosing phase, 55% and 51% of patients treated with T12PR had
rash and pruritus, respectively, compared with 33% and 26% of
placebo-treated patients (Fig. 1A).
In the telaprevir trials, rash events were graded by severity
into four grades (Table 3). More than 90% of rash (SSC) events
with telaprevir were Grade 1 or 2 (mild/moderate). Of the 746
(55%) cases of rash (SSC), 495, 186, and 65 were Grades 1, 2,
and 3, respectively, representing 37%, 14%, and 5% of the overall
T12PR-treated population (Fig. 1B). Examples of Grades 1 and 2
dermatitis are shown in Fig. 2. In the majority (92%) of cases, pro-
gression of rash to a more severe grade did not occur [36]. A small
proportion (6% [78/1346]) of all T12PR-treated patients required
discontinuation of telaprevir as a result of skin conditions. Fol-
lowing treatment discontinuation, symptoms commonly
resolved.
The incidence of rash (SSC) during the telaprevir/placebo
phase and the overall treatment phase are shown in Fig. 1C
[37]. Approximately 50% of rash events started during the ﬁrst
4 weeks, with the remaining 50% starting between weeks 5–12.
The median time to onset of rash (any grade) was 25 (range 1–
350) days [36]. Therefore, skin eruptions can occur at any time
during telaprevir treatment. Following the end of telaprevir dos-
ing at week 12, all patients continued to receive peginterferon/
ribavirin, whereupon it is noticeable that the incidence of rash2 vol. 56 j 455–463 457
Table 3. Grading of telaprevir-associated rash severity in Phase III telaprevir trials [28,29].
Grade Description Management
Grade 1
(Mild)
Localized skin eruption and/or a skin 
eruption with limited distribution, with or 
without associated pruritus
Telaprevir interruption generally not necessary
Grade 2 
(Moderate)
Diffuse skin eruption involving up to 
approximately 50% of body surface area 
pruritus, or mucous membrane involvement 
with no ulceration
Telaprevir interruption generally not necessary
• 
• Consider interrupting ribavirin and/or peginterferon if no 
improvement in eruption within 7 days of stopping telaprevir, or 
earlier if rash worsens
Grade 3
(Severe)
Generalized rash involving EITHER
• >50% of body surface area 
Or rash presenting with any of the following 
characteristics:
• Vesicles or bullae
• 
membranes
Superficial ulceration of mucous
• Epidermal detachment
• Atypical or typical target lesions
• Palpable purpura/non-blanching 
erythema 
Telaprevir must be stopped immediately
• Interrupt ribavirin and/or peginterferon if no improvement in rash 
within 7 days of stopping telaprevir, or earlier if rash worsens
Life-threatening or 
systemic reactions
Stevens-Johnson syndrome (SJS), toxic 
epidermal necrolysis (TEN), drug reaction 
with eosinophilia and systemic symptoms 
(DRESS), erythema multiforme (EM)* 
acute generalized exanthematous 
pustulosis (AGEP), rash that requires 
therapy with systemic corticosteroids
Permanent discontinuation of all treatment is required
⁄ EM is not life threatening. Careful consideration of discontinuing treatment is needed if the reaction appears different to the general dermatitis/rash, gives rise to suspicion
of SJS/TEN or DRESS, or progresses in severity.
Fig. 2. Examples of (A) Grade 1 dermatitis, (B) Grade 2 dermatitis and (C)
DRESS reactions to telaprevir-based therapy.
Table 4. Discontinuation of all study drugs resulting from rash (SSC) AEs in
Phase II and Phase III clinical trials of telaprevir (overall treatment phase) [36].
T12/PR Any T/PR Placebo/PR
N n (%) N n (%) N n (%)
Permanent discontinuation of all study drugs*
Phase II studies 450 28 (6) 566 35 (6) 271 1 (1)
Phase III studies 893 10 (1) 1257 13 (1) 493 0
Permanent discontinuation of telaprevir/placebo only
Phase II/III studies 1346 78 (6) 1823 107 (6) 764 2 (<1)
⁄ Discontinuation based on discontinuation of peginterferon, since per-protocol
patients had to discontinue all other drugs if peginterferon was discontinued.
Reviewwas comparable between telaprevir and placebo-treated
patients.
Severe cutaneous adverse reaction
A systematic retrospective assessment by expert dermatologists
was made of all 221 Grade 3 rash events, rash events leading to
discontinuation of any study drugs, or rash serious AEs occurring
in Phase III telaprevir trials [36]. In total, 208 (94%) of these cases
were reported in patients receiving telaprevir-based therapy
(N = 1257) [28,29]. This assessment revealed 13 patients receiving
a telaprevir-based regimen who presented with a suspected
severe cutaneous adverse reaction (SCAR). Three cases of
Stevens–Johnson Syndrome (SJS, 1 deﬁnite, 1 probable, and 1458 Journal of Hepatology 201possible) and 11 cases of drug reaction with eosinophillia with
systemic symptoms (DRESS, 1 deﬁnite, 2 probable, 8 possible)
were reported (in one patient, both diagnoses were suspected)
[36]. Among the three SJS cases, one occurred 11 weeks after tela-
previr discontinuation and was not considered related to telapre-
vir. Of the two suspected SJS cases that occurred during the
telaprevir treatment phase, one was considered by the expert der-
matologists as possible SJS, and the other as probable SJS. Among
the 11 suspected cases of DRESS, three were conﬁrmed [36]. One
of these DRESS cases has been reported separately and is shown in
Fig. 2 [38]. All cases of reported SJS resolved, 10 cases of reported
DRESS resolved, 1 patient was lost to follow-up.
SJS (and its more severe form, toxic epidermal necrolysis
[TEN]) and DRESS have a very different presentation but also a
different degree of severity. SJS and TEN are very acute events,
with a mortality rate of 25% during hospitalization [39,40]. The2 vol. 56 j 455–463
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rate of mortality for SJS is estimated to be 13%, with a mortality
rate of 39% for TEN [41] depending on the SCORTEN severity
score [42]. DRESS is more progressive and less severe with a mor-
tality of around 10% [39–43]. Both reactions require an early
diagnosis for proper management, which includes discontinua-
tion of treatment (although the need for urgent diagnosis is more
acute with SJS/TEN). Precise documentation and research of risk
factors is also needed to adequately quantify and minimize the
risk posed.Rash management plan
The rate of discontinuation of all study drugs as a result of cuta-
neous AEs was lower in telaprevir Phase III trials than in Phase II
trials, [36] following incorporation of a rash management plan
into the study protocols (Table 4) [28,29]. Although a rash man-
agement plan was implemented during the ongoing Phase II tri-
als, the majority of patients had already completed the telaprevir
dosing period by this time. All patients in Phase III trials, how-
ever, were treated following the implementation of the rash man-
agement plan at the beginning of the trials.
The rash management plan outlined in the Phase III trial pro-
tocols provides clear guidance for HCV-treating physicians on
how to classify (Table 3) and manage rash events, with the objec-
tive of minimizing the impact of cutaneous reactions while
enabling continuation of antiviral therapy where possible
[28,29]. Grade 1 or 2 (mild or moderate) rash does not require
treatment discontinuation, and can be primarily treated using
emollients/moisturizers and topical corticosteroids. Permitted
topical or systemic antihistaminic (including diphenhydramine,
hydroxyzine, levocetirizine, and desloratadine) drugs may also
be used, based on local prescribing guidelines. Regular follow
up is important, with advice to the patient to limit exposure to
sun/heat and wear loose-ﬁtting clothes. Grade 3 rash requires
immediate discontinuation of telaprevir. Symptomatic treatment
as above may also be employed. Ribavirin interruption (with or
without peginterferon) is required within 7 days of stopping tela-
previr if the Grade 3 rash does not improve, or sooner if it wors-
ens [28,29].
However, in case of any reasonable suspicion or diagnosis of
SJS, TEN, DRESS (also known as drug-induced hypersensitivity
syndrome [DHS] or drug-induced delayed multiorgan hypersen-
sitivity), acute generalized exanthematous pustulosis (AGEP), or
a skin rash that is considered life-threatening, patients in Phase
III telaprevir trials were required to immediately and perma-
nently discontinue all medication [28,29].Perspectives on practical guidance for management of
dermatological adverse events with telaprevir
The authors reviewed the available clinical trial data on telapre-
vir-related dermatological AEs and strategies for their manage-
ment, with the aim of providing practical guidance for HCV-
treating physicians. The key conclusions are presented here.
These recommendations seek to allow the physician and patient
the best chance of eradicating HCV, enabling them to recognize
and respond appropriately to serious dermatological events while
optimizing the likelihood for viral clearance with telaprevir-Journal of Hepatology 201based therapy. Furthermore, to avoid exposing patients to the
risk of severe drug-induced cutaneous reaction, HCV-treating
physicians should be able to distinguish between usual dermati-
tis and SCAR.
Key Points
Dermatological manifestations are an existing concern 
during HCV treatment (manifestation of the disease itself 
and peginterferon/ribavirin treatment)
Dermatological adverse events with 
peginterferon/ribavirin tend towards a uniform entity of 
dermatitis: generalized pruritus and skin xerosis, with 
eczematiform lesions
With the advent of the new direct-acting antivirals, 
dermatological manifestations will be seen more 
frequently
In Phase II/III clinical trials with telaprevir, approximately 
half of telaprevir-treated patients had rash. More than 
90% of rash events were Grade 1 or 2 (mild/moderate) 
and did not progress
In a small number of cases, rash led to telaprevir 
discontinuation, with symptoms commonly resolving after 
withdrawal
Dermatological manifestations with telaprevir-based 
therapy were generally similar in type to the reactions 
observed with peginterferon/ribavirin, but with increased 
frequency and severity
According to the telaprevir prescribing information, Grade 
1 or 2 (mild or moderate) dermatological reactions do not 
require treatment discontinuation, and can be primarily 
treated using class 3 topical corticosteroids. Grade 3 
reactions require immediate discontinuation of telaprevir. 
Ribavirin interruption (with or without peginterferon) is 
required within 7 days of stopping telaprevir if the Grade 
3 reaction does not improve, or sooner if it worsens
In the case of a cutaneous reaction which is unlike the 
HCV treatment-associated rash, a patient should be 
assessed for signs that may indicate a severe cutaneous 
reaction such as DRESS or SJS/TEN. In that situation, 
all treatment must be discontinued immediatelyGood skin care practice
In the case of Grade 1 or 2 dermatitis, patients may beneﬁt from
guidance on optimal skin care techniques that could mitigate skin
symptoms and allow optimal antiviral therapy to be maintained
for as long as possible. Emollient creams and lipid-rich lotions,
rather than aqueous lotions or ointments, are effective and
well-accepted by patients and should be prescribed as prophylac-
tic baseline skin treatment. The patient should be instructed that
proper skin care requires at least 15 min and should become a2 vol. 56 j 455–463 459
Fig. 3. Guidance on the efﬁcient administration of a topical steroid: the
ﬁngertip rule. (A) One ﬁngertip of cream equates to around a 0.5 g steroid dose,
(B) sufﬁcient to treat an area equivalent to two palms. By assessing the affected
skin surface by units of palm surfaces, the amount of topical treatment required
for a given treatment interval can be accurately assessed.
Reviewdaily habit in order to become effective. This is best performed
immediately after a shower or bath, when the skin is still
hydrated. Application of the emollient should begin with the
hands, feet, and the skin around the large joints, followed by
the large skin surfaces of the trunk and extremities, and end with
the neck, face, and skin folds. If required, class 3 potent topical
corticosteroids can be used. Dosage can be measured by the ‘ﬁn-
gertip’ rule: one ﬁngertip of cream equates to about 0.5 g, sufﬁ-
cient to treat an area equivalent to two palms. By assessing the
affected skin surface by units of palm surfaces, the therapist
can accurately dose the required amount of topical corticosteroid
required for a given treatment interval. Fig. 3 illustrates the basic
principles of topical steroid dosing. Topical calcineurin inhibitors
such as tacrolimus are not currently indicated, as they may yield
high serum levels when skin barrier function is impaired.Recognition and classiﬁcation of skin eruptions with telaprevir
Dermatological manifestations with telaprevir-based therapy can
be considered to constitute two conditions. The large majority of
cutaneous reactions represent a single dermatitis entity. This
telaprevir-related dermatitis generally begins during the ﬁrst
4 weeks of therapy, but can occur at any time during treatment.
This eczematous dermatitis reaction is similar to reactions
observed with peginterferon/ribavirin, but occurs with increased
frequency and severity. Typical features of such HCV treatment-
associated rash also include pruritus and skin dryness, and it is
stable or slow to progress. Continuation of telaprevir together
with peginterferon/ribavirin treatment is possible in Grade 1 or
2 (mild or moderate) cases, or Grade 3 cases with appropriate
management (see below). In contrast, a small remainder of cases
can be classiﬁed as SCAR, which is typically rare but potentially
life-threatening if unrecognized or unmanaged, mandating
immediate treatment discontinuation.Management of grades 1–3 telaprevir-associated dermatitis
In line with the rash management plan implemented in Phase III
trials, the telaprevir prescribing information stipulates that Grade
1 and 2 dermatological reactions to telaprevir do not require
treatment interruption, but that Grade 3 reactions require tela-
previr discontinuation followed by ribavirin and/or peginterferon
discontinuation within 7 days if the reaction does not improve, or
sooner if it worsens [27].460 Journal of Hepatology 201In some cases, Grade 3 dermatitis reactions affectingmore than
50%of body surface area butwithno signs of SJS, TEN,DRESS, EMor
AGEP may be manageable using topical corticosteroids without
treatment discontinuation. In such cases, however, hospitalization
of the patient is required, and experienced dermatologists should
be responsible for patient management and close follow up for
signs of progression. It is important for physicians to be aware of
the prescribing information for telaprevir and local guidelines for
management of dermatological adverse drug reactions.
Appropriate guidelines, as evidenced from the Phase III stud-
ies of telaprevir (Table 3), permit the continuation of peginterfer-
on/ribavirin treatment after the cessation of telaprevir in order to
optimize the chance of SVR while minimizing the risk of DRESS or
SJS. The less common but potentially life-threatening reactions
such as SJS, TEN, and DRESS require cessation of all treatment.
AGEP is generally characterized by an acute, widespread edem-
atous erythema with the presence of small non-follicular pustulo-
sis mostly in the folds and the face, and is associatedwith elevated
neutrophils andhigh fever [40,44]. The reaction lasts for a fewdays.
While EM is not a life-threatening reaction, there has been some
historical confusion between EM and the separate entity of SJS
[39,45]. Ensuring the correct diagnosis is made and appropriate
action is taken is therefore important when considering discon-
tinuing antiviral treatment. While SJS is drug-induced, EM usually
occurs post-infection and is characterized by typical target lesions,
chieﬂy on the extremities, rather than the widespread macules or
blisters associated with SJS [39]. Target lesions are deﬁned as less
than 3 cm in diameter, with at least 3 ‘zones’: a central zone of
dusky erythema or purpura (sometimes blistering), a middle paler
area of oedema, and awell-deﬁned outer ring of erythema [46]. All
other target lesions lacking this pattern of three zones should be
considered atypical target lesions. In cases of suspicion of EM, we
would advise that telaprevir discontinuation shouldbe considered,
and implemented if the reaction appears different to the general
dermatitis reaction, gives rise to any reasonable suspicion of SJS/
TEN or DRESS, or progresses in severity.
The severity of telaprevir-associated dermatitis events dic-
tates the frequency of evaluation by the HCV-treating physician.
In the case of a Grade 1 event, it is recommended that the patient
should be re-evaluated between days 2 and 4 after the onset of
rash. Patients with a Grade 2 event should be seen at day 2. Grade
3 events require follow up on days 1, 3, and 7. Additional regular
follow-up of patients is required until the reaction is completely
resolved.
Guidance for distinguishing between telaprevir-related dermatitis
and SCAR
In accordance with the Phase III rash management plan, and in
contrast to the telaprevir-related dermatitis, SJS, TEN, DRESS,
EM, and AGEP reactions require immediate discontinuation of
all treatment (telaprevir, peginterferon, and ribavirin) and refer-
ral to a dermatologist. A number of clinical and biological signs
and symptoms have been identiﬁed from the clinical trial data-
base that may help HCV-treating physicians to distinguish
between telaprevir-related dermatitis, where antiviral treatment
can often be continued and supportive treatment given, and the
less common but potentially more harmful SJS and DRESS reac-
tions. These are illustrated in the algorithm in Fig. 4 and out-
lined below.2 vol. 56 j 455–463
• Onset at any time (often during  4 weeks)
• Pruritus
• Dryness
• Eczematous
• Slow progression or stable
Refer to rash management plan. Grade 1 or 2 rash does not 
require treatment discontinuation and can be treated with topical 
corticosteroids and permitted topical or systemic antihistamines
In the case of a cutaneous reaction which is unlike the HCV 
treatment-associated rash, assess patient for signs that may 
indicate severe cutaneous reaction such as DRESS or SJS/TEN:
When to suspect DRESS:
Alert criteria
1. Onset from 5-10 wk after 
 dose
2. Rapidly progressing 
exanthema
3. Prolonged fever (>38.5 ºC)
4. Facial edema
If any DRESS alert criteria are 
found, the patient should be 
assessed for the following 
1. Enlarged lymph node
2. Eosinophilia (≥700/µl or 
≥10%)
3. Atypical lymphocytes
4. Rise in ALT, alkaline 
phosphatases (≥2 times upper 
limit of normal value)
5. Rise in creatinine 
(≥150% basal level)
criteria are also found, all 
treatment should be 
discontinued immediately and 
the patient should be referred 
to a dermatologist
When to suspect SJS or 
TEN:
1. Rapidly progressing 
exanthema
2. Skin pain
3. Mucosal involvement at 
≥2 sites
4. Blisters or epidermal 
detachment (not only at 
PEG-IFN injection site)
5. Atypical/typical target 
lesions
If symptoms 3 or 4 are 
present, all treatment should 
be discontinued immediately 
and the patient should be 
referred to a dermatologist
Characteristics of HCV treatment-associated rash
(>90% of cutaneous reactions):
first
first
DRESS confirmation criteria:
Confirmation criteria
If any DRESS confirmation
Fig. 4. Algorithm for distinguishing between telaprevir-related dermatitis
and SCAR in a rapidly progressing skin reaction. DRESS: drug reaction with
eosinophilia and systemic symptoms (also known as drug-induced hypersensi-
tivity syndrome); SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrol-
ysis; ALT, alanine transaminase.
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Journal of Hepatology 201Patients with a rash that appears to be unlike the telaprevir-
associated dermatitis should be assessed for signs that may
indicate possible DRESS. Criteria that should alert the physician
include onset from 5 to 10 weeks after ﬁrst dose, rapidly pro-
gressing skin rash, prolonged fever (>38.5 C), and facial edema.
If any of these signs are present, the patient should be urgently
examined for the following ‘conﬁrmation criteria’: enlarged
lymph nodes, eosinophilia, atypical lymphocytes, and rise in ala-
nine transaminase, alkaline phosphatase or creatinine. If any
conﬁrmation criteria are found, telaprevir, peginterferon, and
ribavirin treatment should be discontinued immediately and
permanently, and the patient referred to a dermatologist. It is
important to note that there is a greater urgency for prompt
diagnosis and appropriate action for SJS and TEN. Patients pre-
senting with mucosal involvement of at least two sites, or with
blisters or epidermal detachment (at sites beyond the site of
peginterferon injection) should immediately and permanently
discontinue telaprevir, peginterferon, and ribavirin and be
referred to a dermatologist. Rapidly progressing skin rash, skin
pain, and atypical or typical target lesions may also be present
in cases of SJS or TEN and should alert the physician to assess
the patient for mucosal involvement, blisters or positive Nikol-
sky signs (epidermal detachment under lateral pressure on
erythema).Summary and conclusions
HCV and its treatment with peginterferon/ribavirin are associ-
ated with signiﬁcant dermatological complications. In the era of
DAA-based triple combination therapy, however, management
of dermatological AEs will become an even more important con-
sideration for HCV-treating physicians. Effective management
strategies will be of great importance in limiting the severity
and impact of dermatological side effects on treatment outcomes.
The majority of cutaneous AEs occurring with telaprevir can
be classiﬁed as a less harmful eczematous dermatitis, associated
with pruritus and xerosis. Most cases of this dermatitis reaction
are mild or moderate, in which case good skin care practice, cou-
pled with vigilance for the rare signs of more serious reactions,
should enable antiviral therapy (peginterferon/ribavirin with or
without telaprevir) to be maintained in order to increase the
chances of patients achieving an SVR. Rare cases of severe cutane-
ous reactions including DRESS and SJS have been reported and
resolved upon antiviral treatment discontinuation. Even though
these cases are rare, special attention to skin symptoms occurring
during HCV treatment and strict adherence to the rash manage-
ment plan is required in order to detect severe cutaneous reac-
tions as early as possible.Conﬂict of interest
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